Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bevacizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Outlook Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.
Brand Name : ONS-5010
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Bevacizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Outlook Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?